3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Urinary Bladder Neoplasms
5
Melanoma
2
Glioblastoma
2
Brain Neoplasms
2
Urothelial Carcinoma of the Bladder
1
Squamous Cell Carcinoma of Head and Neck
1
Oligodendroglioma
1
Non-Muscle Invasive Bladder Urothelial Carcinoma
1
Non-Muscle Invasive Bladder Neoplasms
1
Neuroblastoma
1
Nasopharyngeal Carcinoma
1
Mouth Neoplasms
1
Lymphoma, Follicular
1
Laryngeal Neoplasms
1
Glioma
1
Ganglioneuroblastoma
1
Craniopharyngioma
1
Carcinoma
1
Astrocytoma
1
Interventions
pembrolizumab
2
durvalumab
2
Tretinoin
2
Paclitaxel
2
Oxaliplatin
2
Irinotecan
2
Chemoradiotherapy
2
Carboplatin
2
Capecitabine
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
tislelizumab
1
tegafur-gimeracil-oteracil
1
talazoparib
1
sarilumab
1
relugolix
1
pexidartinib
1
pertuzumab
1
patritumab
1
olaparib
1
niraparib
1
neratinib
1
ganitumab
1
enzalutamide
1
dostarlimab
1
cemiplimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Pathologic Complete Response
×
Transurethral Resection of Bladder
×
90 days
×
Clear all
No trials found.